Neurogenic Bladder Disorder
Conditions
Keywords
Onabotulinumtoxin A; Neurogenic lower urinary tract dysfunction; Urodynamics
Brief summary
Purpose: To evaluate urodynamic parameters predicting the treatment efficacy of onabotulinumtoxin A (onaBoNT-A) in patients with neurogenic lower urinary tract dysfunction (NLUTD). Methods: Patients with NLUTD who received 200 IU onaBont-A injections at Gaziantep University, Faculty of Medicine, Department of Urology between September 2013 and September 2023 were included in the study. Urodynamic parameters, including cystometric capacity, detrusor pressure (Pdet), and compliance, detrusor leak point pressure (DLPP), phasic or terminal neurogenic overactivity were assessed. Additionally, the correlations between these parameters and treatment outcomes were analyzed. Changes in the number of pads used per day due to UI were assessed every 3 months during the postoperative period. The time lapsed to return to the pad usage levels before onaBoNT-A injections was recorded as the duration of the benefit. Preoperative urodynamic data of the patients were compared between groups. Additionally, a subgroup analysis was conducted in patients who benefited from treatment to evaluate the correlation between treatment efficacy, duration of benefit from treatment, and urodynamic parameters.
Interventions
Treatment effect and duration of Onabotulinum Toxin A according to patient's pad usaged
Sponsors
University of Gaziantep
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with Neurogenic Lower Urinary Tract Disorder * Aged \>18 years * Patients who did not respond adequatel to antimuscarinics or could not tolerate their side effects * Antimuscarinic treatment failure with at least two different antimuscarinic agents for a minimum of 3 months.
Exclusion criteria
* Patients with Lower Urinary Tract Disorder due to functional or non-neurogenic etiologies * Patients who received onaBoNT-A doses either other than 200 IU or its multiple doses * In the 12-month period designated for patient follow-up, patients who did not attend their check-ups
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of patients after onabotulinum a toxin injections who respond to treatment | received 200 IU of onaBoNT-A injections for the first time, and followed up regularly for the duration of at least 12 months. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| treatment succes duration of patients | Received 200 IU of onaBoNT-A injections for the first time, and followed up regularly for the duration of at least 12 months. | The duration of the decrease in the number of pads used was calculated |
Outcome results
None listed